Kornimate/medical-research-clean huggingface dataset:
investigating event-related potentials and eye-tracking measures in hockey players

Conditions: Healthy; Traumatic Brain Injury

Summary: traumatic brain injury (tbi) is a health issue impacting athletes and no clinical treatment protocol, other than rest, is yet established. the efficacy of a treatment protocol relies on objective, physiological measures of brain function and ultimately a quantification of injury severity. the present study aims to assess neurophysiological markers of auditory and visual measures of brain function using the neurocatch platform and eye-tracking technology, respectively. the current gold standard of tbi evaluation, including cognitive and balance assessments, will also be captured.


Eligibility criteria:
inclusion criteria: * any sex, 14-25 years old inclusively * attending the creative artists agency llc (caa) hockey camp in july 2019 * able to understand the informed consent/assent form, study procedures and willing to participate in study neurocatch platform-specific inclusion criteria * able to remain seated and focused for 6 minutes * normal hearing capabilities exclusion criteria: • unable to provide informed consent neurocatch platform-specific exclusion criteria * clinically documented hearing issues (e.g. tinnitus, in-ear hearing problems or punctured ear drum) * in-ear hearing aid or cochlear implant, hearing device * implanted pacemaker or defibrillator * metal or plastic implants in skull * exposed to an investigational drug or device 30 days prior to start in this study, or concurrent or planned use of investigational drug or device during hockey camp (july 7th - 13th 2019) * not proficient in english * previous exposure to the neurocatch™ platform audio sequences in the last 6 months * history of seizures * allergy to rubbing alcohol or eeg gel * unhealthy scalp (apparent open wounds and/or bruised or weakened skin)
pericapsular nerve group block for elective hip arthroplasty

Conditions: Postoperative Pain

Summary: this study examine the effect of pericapsular nerve group (peng) block on analgesia after elective hip arthroplasty. half of participants will receive a peng block with local anesthetic, while the other half will receive a peng block with a placebo.

optimized analgesia is crucial for early mobilization after hip arthroplasty. regional anesthesia, like fascia iliaca block or femoral nerve block, have limited indication because of motor blockade whereas local infiltrations analgesia have shown conflicting analgesic efficacy results in hip arthroplasty. pericapsular nerve group (peng) block is a new regional anesthesia technique targeting specifically sensory nerve branches of the hip articulation. it has been originally described in hip fracture patients. the aim of this study is to evaluate the efficacy of peng block on analgesia after elective hip arthroplasty.

Eligibility criteria:
inclusion criteria: * elective total hip arthroplasty * general anesthesia * enhanced recovery program exclusion criteria: * american society of anesthesiologists (asa) score \> 2 * drug allergy * significant psychiatric disturbances * preoperative opioid use * contraindication to acetaminophen, celecoxib, methylprednisolone or tranexamic acid * body mass index \> 40 kg/m²

Keywords: elective hip surgery peng block
initial clinical experience with the monarch platform, urology for the treatment of kidney stones

Conditions: Kidney Calculi

Summary: the purpose of this study is to collect descriptive performance data using the monarch platform, urology (a novel robotic device) to perform mini-percutaneous nephrolithotomy (kidney stone removal) procedures. data gathered from this study will be used to optimize the robotic platform and inform training and education material for the future users.


Eligibility criteria:
inclusion criteria: * simple renal caliceal and/or pyelo stone(s), greater than or equal to (\>=) 10 millimeter in size identified on computerized tomography (ct) scan, and appropriate for percutaneous nephrolithotomy (pcnl) treatment according to american urological association (aua) guidelines * normal upper tract anatomy, amenable to pcnl and ureteroscopy * body mass index less than (\<) 40 kilogram-meter squared * participants with a percutaneous tract length \<15 centimeter as measured by the estimation of the skin to stone or skin to appropriate calyx for treatment through a ct scan * participant is an appropriate candidate for a mini-pcnl based on the clinical guidelines and investigator assessment pre-operative exclusion criteria: * any medical or physical condition/limitation that would contraindicate a conventional ureteroscopy or pcnl \[for example, atypical interposition of visceral organs (bowel, spleen, or liver)\] in the supine position. this assessment will be made by the investigator team * participation in any other clinical trial 30-days before and throughout the duration of the study that might impact the results * a solitary functioning kidney * female subjects who are pregnant or nursing or those of childbearing potential refusing a pregnancy test * presence of ureteral impacted stones * presence of ureteral obstruction * presence of untreated urinary tract infection, urosepsis * inability to give consent * presence of a renal mass which has not been investigated * staghorn stone * participant has an electrically or magnetically activated implanted medical device * significant pharmacological anticoagulant therapy or uncorrected bleeding diathesis * tumor in the probable access tract area and potential malignant renal tumor intra-procedure exclusion criteria: - any presenting condition discovered intra procedurally that in the opinion of the investigator would make participating in this study not in the participant's best interest. for example, participants no longer considered good candidates for a mini-pcnl procedure for the removal of the kidney stones.

Keywords: nephrolithotomy, percutaneous, ureteroscopy, robotic, monarch, kidney calculi
a web-based intervention to prevent drug abuse among adolescent girls

Conditions: Drug Abuse Prevention

Summary: this study is designed to develop and test a gender-specific, web-based drug abuse prevention program. study participants will be adolescent girls aged 13 and 14 years who will complete all measures online. randomly assigned girls will also interact online with a skills-based program and subsequent annual booster sessions. the study's primary hypothesis is that rates of 30-day alcohol and drug use will be lower among girls assigned to receive the intervention.


Eligibility criteria:
inclusion criteria: * resident of usa * speaks english * have private computer with internet exclusion criteria: -

Keywords: gender-specific web-based drug abuse prevention
tolerability of an anesthesia-free tonometer tip

Conditions: Glaucoma

Summary: the purpose of this study is to compare the tolerability and comfort of 3 different prototype anesthesia-free tonometer tips with the standard tonometer tip in conjunction with anesthesia. the best-tolerated prototype anesthesia-free tonometer tip will be identified for further development for home tonometry.


Eligibility criteria:
inclusion criteria: * presenting for a routine eye exam * ≥ 18 years of age * able and willing to give consent exclusion criteria: * history of corneal scarring * active infection of the eye * history of alternated corneal sensitivity * history of corneal surgery
running study for runners with chronic knee pain

Conditions: Patellofemoral Pain Syndrome

Summary: the purpose of this study is to determine whether changing foot strike pattern from a rearfoot strike to a forefoot strike reduces chronic running-related knee pain. it is believed that switching foot strike pattern from a rearfoot strike to a forefoot strike pattern will reduce associated running-related patellofemoral knee pain.

runners will come to the gait analysis lab on north campus of the university of new mexico, hssb 168, for the first running trial. during this time you will fill out a health questionnaire, receive an assessment by a physical therapist, and be given a new pair of running shoes to use for the duration of the study. runners will be equipped with several reflective markers, which will be placed on your lower body. runners will then complete several passes across a runway while we record your running with a motion analysis system. runners will be equipped with a mouthpiece and nose clip. you will run for 10 minutes while we collect the gases you breathe.twenty-four hours after you complete this running trial, you will come to our exercise physiology lab in johnson center, b143 to perform the training sessions. during this time you will run for about 10-30 minutes in front of a mirror and receive feedback from the research team. you will perform these training sessions eight times over two weeks. twenty-four hours after your last training session, you will perform another follow-up running trial, which will be the same as the first trial. after completing the second running trial, you will be allowed to return to your normal running routine for about one month. after one month, you will return to the gait analysis lab to perform a final running trial, which will be the same as the first and second running trials.

Eligibility criteria:
inclusion criteria: 1. presence of patellofemoral pain 2. no history of any cardiovascular issues. 3. currently running as part of training program exclusion criteria: 1. no patellofemoral pain present. 2. not currently running as part of training program 3. other lower extremity pain and/or injury that interferes with ability to run. 4. pregnant 5. not in the selected age ranges 6. presence of cardiovascular or cardiopulmonary diseases
brachial plexus block in children and adolescents

Conditions: Upper Extremity Fracture

Summary: this study involves a retrospective evaluation of brachial plexus anaesthesia in children and adolescents (patients under the age of 18) undergoing surgical procedures of the upper extremity following trauma. the investigators plan to recruit patients from our hospital patient database meeting our inclusion criteria. observational period was defined between 1st of january 2002 and 31st of october 2018. necessity to convert to general anaesthesia was defined as primary endpoint.


Eligibility criteria:
inclusion criteria: * brachial plexus anaesthesia for surgical intervention of upper extremity injuries exclusion criteria: * age above 18
effect of oral health educational program on the oral health related quality of life in a group of children with chronic kidney disease

Conditions: Chronic Kidney Disease(CKD)

Summary: children with ckd are at higher risk for poor oral health28 due to factors such as compromised immunity, medication side effects, and dietary restrictions. poor oral health can lead to pain, infection, and difficulties in eating and speaking, which in turn negatively affects their quality of life. this study is designed to address this gap by exploring how an oral health educational program could improve the oral health-related quality of life (ohrqol) in this group.


Eligibility criteria:
inclusion criteria: * age 8-10 years old. * diagnosed with chronic kidney disease exclusion criteria: * children with other systemic diseases. * parents that refuse the participation of their children.

Keywords: ckd ohrql ohep
safety and efficacy study of mesenchymal stem cell in treating kidney fibrosis

Conditions: Renal Cirrhosis

Summary: in progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. the potential for stem cells to treat kidney failure was recently confirmed. particularly, mesenchymal stem cell (msc) has been demonstrated to protect kidney function and alleviating renal injury in these patients. therefore, the investigators propose a hypothesis that mscs (msc) can also improve the disease conditions of kidney fibrosis patients, particularly reducing the decompensated conditions in these patients.

kidney fibrosis represents the common pathway to end-stage kidney failure.the potential for stem cells to treat kidney failure was recently confirmed. in particular, mesenchymal stem cell (msc) transplantation has been applicated in the clinic for treat several human diseases such as gvhd, kidyney injury and displayed good tolerance and efficiency. the purpose of this study is to learn whether and how mscs (msc) can improve the disease conditions in patients with kidney fibrosis. this study will also look at safety in these patients.

Eligibility criteria:
inclusion criteria: 1. written informed consent. 2. glomerular sclerosis ratio ≤ 50%. 3. renal tubulointerstitial fibrosis ratio ≤ 50%. 4. negative pregnancy test. 5. moderately active disease under standard treatment. exclusion criteria: 1. severe infection and cardiovascular disease, shock, secondary liver disease and malignant tumor.
prospective cohort study of patients with infective endocarditis at pitié-salpêtrière hospital

Conditions: Infective Endocarditis

Summary: infective endocarditis (ie) is a severe condition associated with high mortality. due to the relative low prevalence of ie, prospective data are lacking and current guidelines are mostly based on expert consensus with low level of evidence. ie is also associated with severe complications especially strokes that occur in about one third of the patients. in order to improve the management and the prognosis of ie, clinical data from larges prospective cohort studies are needed.

the study will take place at the cardiology institute of the pitié-salpêtrière hospital. all patients referred to this tertiary care center for ie management will be included. the characteristics of the patients (demographics, clinical, laboratory, and imaging data) at the time of ie diagnosis and during the follow-up will be collected. the patients will be followed up to 10 years after inclusion.

Eligibility criteria:
inclusion criteria: * patients with confirmed ie according to european society of cardiology criteria exclusion criteria: * opposition of the patient to participate

Keywords: infective endocarditis, prospective, prognosis, biomarker, embolism
a multiple oral doses study of pf-06427878 in healthy adult subjects

Conditions: Healthy Subjects

Summary: pf-06427878 is a new compound proposed for the treatment of hyperlipidemia. the primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of pf-06427878 in healthy adult subjects.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects of non childbearing potential. * body mass index (bmi) of 17.5 to 35.4 kg/m2; and a total body weight \>50 kg * subjects with fasting tg level of \>=90 mg/dl and \<=500 mg/dl following an overnight fast * subjects with low density lipoprotein cholesterol between 115 mg/dl and 190 mg/dl following an overnight fast exclusion criteria: •evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Keywords: multiple ascending dose healthy subjects hyperlipidemia lipid metabolism disorders metabolic diseases
gm-csf with post-transplant cyclophosphamide

Conditions: Transplant-Related Hematologic Malignancy

Summary: given the increased number of hla-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that gm-csf administration post-infusion of t-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to g-csf with a potential of lowering risk of infectious complications.


Eligibility criteria:
inclusion criteria: * availability of 5/10 to 8/10 matched related donor * kps \>/= 70% * cml, aml, mds, all, cll, hd, nhl, mps/cmml, mm, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center exclusion criteria: * poor cardiac, pulmonary, liver, and renal function * hiv-positive * patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent * history of severe or serious allergic reaction to human gm-csf or yeast-derived products
cardiac magnetic resonance guidance of implantable cardioverter defibrillator implantation in non-ischemic dilated cardiomyopathy

Conditions: Non-ischemic Dilated Cardiomyopathy

Summary: patients with diagnostic cmr images for assessment of lge/fibrosis and evidence/presence of non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups in a 1:1 ratio: icd group or optimal hf care group.

the primary objective of this study is to evaluate the hypothesis that implantable cardioverter defibrillator (icd) therapy would decrease the risk of death from any cause in comparison to optimal heart failure (hf) care without icd insertion in patients with nidcm, left ventricular ejection fraction (lvef) ≤35% and presence of myocardial fibrosis on cardiac magnetic resonance (cmr) imaging.

Eligibility criteria:
inclusion criteria: * nidcm (idiopathic or familial)\* * lvef ≤35% and presence of fibrosis on cmr * diagnostic cmr scan * age ≥18 years * written informed consent * ability to give informed consent exclusion criteria: * icm \[previous myocardial infarction, previous percutaneous coronary intervention\] * other cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathies \[e.g. cardiac amyloidosis, cardiac sarcoidosis, hemochromatosis and iron overload cardiomyopathy\], left ventricular non-compaction cardiomyopathy, reversible cardiomyopathies \[takotsubo syndrrome, peripartum cardiomyopathy, chemotherapy induced cardiomyopathy\]. * myocarditis * contraindication for cmr at study entry (including severe claustrophobia, pacemaker or icd, metallic cerebral or intracranial implants, known allergy to gadolinium) * severe renal insufficiency (creatinine clearance \<30 ml/min) * current pacemaker or defibrillator in situ * current indication for device therapy (e.g. secondary prophylaxis after aborted scd) * renal impairment defined as an egfr \<30 milliliters * age \<18 years * patients presenting with pregnancy * patients without informed consent * participation in another randomized trial * life expectancy \<2 years
innovative bed apparatus for pediatric pain and anxiety relief

Conditions: Pain Management; Anxiety

Summary: pain and anxiety are common responses in pediatric patients undergoing invasive procedures and can negatively affect both immediate care outcomes and future health-care experiences. non-pharmacological interventions, especially those involving multisensory distraction, are increasingly used to alleviate distress. this study aimed to evaluate the effectiveness of a novel, child-friendly, multisensory support device in reducing pain and anxiety in pediatric surgical patients. keywords: child, pain, anxiety, distraction, pediatrics, innovative device

this randomized controlled trial included 48 children aged 4-12 years who were hospitalized in the pediatric surgery unit of a tertiary hospital in istanbul, turkey, and who underwent an invasive procedure for the first time. participants were randomly assigned to either the intervention (n=24) or control group (n=24) using block randomization based on age and sex. the intervention group received a multisensory pediatric support device that delivered combined audio (storybook narration), visual (lights), and animated stimuli during the procedure. the control group received standard preoperative and postoperative care. pain and anxiety were measured using the wong-baker faces pain rating scale and the children's anxiety meter state (cam-s), respectively.

Eligibility criteria:
inclusion criteria: children aged 4 to 12 years. hospitalized in the pediatric surgery ward. undergoing an invasive intervention (e.g., intravenous catheter insertion, intramuscular injection, wound care) for the first time during their hospital stay. able to communicate and understand simple instructions. written informed consent obtained from legal guardians and verbal assent from the child (as appropriate to developmental level). exclusion criteria: * children with cognitive impairments or developmental delays that prevent communication or reliable self-reporting. children with previous experience of invasive procedures during the current hospitalization. children receiving sedation or pharmacological anxiolytics before the procedure. children or legal guardians who refuse to provide informed consent.

Keywords: child pain anxiety distraction innovative device
thrombosis outcomes in pediatric venous thromboembolism

Conditions: Venous Thromboembolism

Summary: 'the top study' is a prospective cohort study whose main objective is to develop better prognostic biomarkers and identify children at risk of adverse thrombotic outcomes very early in the course after an initial venous thromboembolic events (vte). the study will compare biomarkers in children that develop poor vte outcomes (such as recurrence, postthrombotic syndrome and post pe impairment ) after an initial vte with those that do not develop such outcomes.

all newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at children's medical center, dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored for development of carefully defined adverse vte outcomes in a blinded manner. biomarker assessment will include global coagulation assays (thrombin generation assay and modified thromboelastography to study fibrinolysis) at 3, 6, 12, 18 and 24 months post vte diagnosis.

Eligibility criteria:
inclusion criteria: * boys and girls age birth (0 years) to equal to or less than 21 years * a radiologically confirmed first venous thromboembolism episode (both extremity and non-extremity) who have completed anticoagulation therapy as per the 9th edition of the accp guidelines exclusion criteria: * known malignancy * pregnancy or immediate post-partum period (12 weeks after delivery) * sickle cell disease * known bleeding disorder

Keywords: blood clot deep vein thrombosis pulmonary embolism lower extremity upper extremity cerebral sinus renal vein portal vein thrombin fibrinolysis coagulation anticoagulation post trombotic syndrome post pulmonary embolism syndrome chronic thromboembolic pulmonary hypertension
optimization of 99mtc-sestamibi activities in spect/ct myocardial perfusion imaging

Conditions: Coronary Heart Disease

Summary: this work suggests a methodology to adapt the injected radionuclide activity to the level of attenuation of each patient. the investigators propose a dose reduction adapted to the patient's weight, with no significant degradation of the image quality, in order to improve patients and staff radioprotection, standardize the image quality for easier clinical interpretation, and lead to radiopharmaceutical saving in the context of myocardial perfusion imaging.


Eligibility criteria:
inclusion criteria: * patient underwent stress-test 99 mtc-sestamibi spect/ct myocardial perfusion imaging on a siemens intevo bold anger camera with the cardiofocal smartzoom® collimator exclusion criteria: * none

Keywords: myocardial spect sestamibi smartzoom cardiofocal collimator dose optimization